Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Factors influencing development of SAEs in patients with RA treated with TCZ or TNFIs a

From: Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry

Variable All patients MTX users
HR (95% CI) c P value c HR (95% CI) d P value d
Age by decade 1.47 (1.15 to 1.88) 0.002 1.58 (1.07 to 2.35) 0.022
Female 0.74 (0.40 to 1.38) 0.345 0.96 (0.38 to 2.47) 0.940
DAS28CRP (3) 1.06 (0.98 to 1.14) 0.151 1.06 (0.76 to 1.48) 0.744
Comorbidityb 1.86 (1.07 to 3.24) 0.029 2.10 (0.92 to 4.79) 0.077
PSL ≥5 (mg/day) 1.72 (1.01 to 2.93) 0.047 1.64 (0.74 to 3.63) 0.223
Steinbrocker’s Class 3 or 4 1.37 (0.77 to 2.43) 0.287 1.10 (0.47 to 2.60) 0.825
Tocilizumab 1.28 (0.75 to 2.19) 0.370 1.21 (0.55 to 2.65) 0.632
  1. aCox regression analysis with the independent variables included in the Table; bcomorbidity included pulmonary diseases, diabetes mellitus, liver diseases, and kidney diseases; cCox regression analysis was applied in all patients; dCox regression analysis was applied in patients who were treated with MTX at baseline. CI: confidence interval; CRP: C-reactive protein; DAS28CRP (3): 3-variable disease activity score including 28-joint count; HR: hazard ratio; MTX: methotrexate; PSL: prednisolone RA: rheumatoid arthritis; SAEs: serious adverse events; TCZ: tocilizumab; TNFIs: tumor necrosis factor inhibitors.